Immix Biopharma Stock Plummets After Report Reveals CMO Was a Fugitive

Shares of Immix Biopharma (NASDAQ: IMMX) fell sharply in morning trading, sliding as much as 11.6%, after a news report exposed that its Chief Medical Officer was a long-time fugitive arrested by federal authorities.

Governance Under Scrutiny

The sell-off was triggered by an investigative report published by STAT News, which revealed that the company's CMO, hired in March 2026 under the name "Dr. Richard Graydon," was actually Ronald Fischer. Fischer, 70, a former anesthesiologist, had been a fugitive since disappearing in 2005 while on trial for first-degree sexual assault in Rhode Island, the report stated.

According to the source, Fischer was arrested the week of July 13, 2026, after authorities tracked him to a sailboat off the coast of New Jersey. In response to the events, Immix Biopharma announced in an 8-K filing that "Graydon" had been terminated from his position.

Market Impact

Ad

The stock's decline was exacerbated by significant short interest, which had nearly doubled in June 2026. With approximately one-in-five shares sold short, the negative news provided fuel for an accelerated sell-off.

This was a company-specific event, with the broader market offering no downward pressure. The NASDAQ Composite was up 0.5% and the S&P 500 gained 0.2% during the session, underscoring the isolated nature of Immix's stock plunge. Shares fell to a low of $8.73, significantly off the 52-week high of $12.14.

Critical Timing

The revelation comes at a particularly sensitive time for Immix Biopharma, which is approaching a pivotal data announcement. The company expects to release topline data from its BLA-enabling NEXICART-2 trial in the third quarter of 2026. The scandal raises immediate concerns among investors about the company's corporate governance and due diligence procedures just weeks before this crucial milestone.